Clinical Trials Sponsored by Shanghai Jiatan Pharmatech Co., Ltd

Total 1265 results

Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Shanghai Longwood Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Advanced Solid Tumor

China
Shanghai Yuyao Biotech Co., Ltd.

Active, not recruiting

An Phase I Study of YY001 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Completed

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Generalized Pustular Psoriasis

China
Shanghai SIMR Biotechnology Co., Ltd.

Completed

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

China, Australia
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer (B003-101)

HER2-positive Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Active, not recruiting

Study of Efficacy and Safety of GR1501 in Patients With Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects

Alzheimer's Disease

China
Shanghai Zerun Biotechnology Co.,Ltd

Active, not recruiting

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

COVID-19 | SARS-CoV-2 Infection

Mali
Shanghai Zerun Biotechnology Co.,Ltd

Completed

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

HPV Infections

China
Shanghai Bao Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

Healthy

New Zealand
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

An Evaluation of 9MW1911 Injection in Healthy Subjects

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT)

Triple-Negative Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children

Preoperative Sedation of Children

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Drug-drug Interaction Study of SPH3127

Drug Drug Interaction

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Postmenopausal Osteoporosis

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma
Nuance Pharma (shanghai) Co., Ltd

Completed

Evaluate the Pharmacokinetics and Safety of EXPAREL® Following Subcutaneous Administration in Healthy Chinese Subjects

Healthy Subjects

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Shanghai Gebaide Biotechnology Co., Ltd.

Unknown

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Non-small-cell Lung Cancer (NSCLC) Stage IV

China
Shanghai Zerun Biotechnology Co.,Ltd

Unknown

Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females

Human Papillomavirus

China
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Daewoong Pharmaceutical Co. LTD.
Shanghai Haini Pharmaceutical Co., Ltd.

Active, not recruiting

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

Phase 1 Study, Healthy Volunteers

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

COVID-19

China
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Psoriasis

Psoriasis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan

Clinical Trials Sponsored by Shanghai Jiatan Pharmatech Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations